

# 33 - References

## References

834 The Maudsley® Prescribing Guidelines in Psychiatry CHAPTER 10 Cognitive symptoms  
Cognitive disturbances may emerge many years before motor disturbances.<sup>7</sup> The progression of cognitive decline is gradual<sup>25</sup> and dementia is inevitable in late stages. Although a wide variety of agents have been studied,<sup>2,11</sup> none has become established treatment and the benefit of most remains unclear.<sup>26</sup> There is insufficient evidence to support the use of acetylcholinesterase inhibitors<sup>27</sup> and no evidence to support any other medications to treat dementia in HD.<sup>11,28</sup>  
References

1. Medina A, et al. Prevalence and incidence of Huntington's disease: an updated systematic review and meta-analysis. *Mov Disord* 2022; 37:2327-2335.
2. Ferreira JJ, et al. An MDS evidence-based review on treatments for Huntington's disease. *Mov Disord* 2022; 37:25-35.
3. Mestre T, et al. Therapeutic interventions for disease progression in Huntington's disease. *Cochrane Database Syst Rev* 2009; 2009:CD006455.
4. Van de Roovaart HJ, et al. Huntington's disease drug development: a phase 3 pipeline analysis. *Pharmaceuticals (Basel)* 2023; 16:1513.
5. Killoran A, et al. Current therapeutic options for Huntington's disease: good clinical practice versus evidence-based approaches? *Mov Disord* 2014; 29:1404-1413.
6. Anderson KE, et al. Clinical management of neuropsychiatric symptoms of Huntington disease: expert-based consensus guidelines on agitation, anxiety, apathy, psychosis and sleep disorders. *J Huntingtons Dis* 2018; 7:355-366.
7. McColgan P, et al. Huntington's disease: a clinical review. *Eur J Neurol* 2018; 25:24-34.
8. Bachoud-Lévi AC, et al. International guidelines for the treatment of Huntington's disease. *Front Neurol* 2019; 10:710.
9. Furr Stimming E, et al. Safety and efficacy of valbenazine for the treatment of chorea associated with Huntington's disease (KINECT-HD): a phase 3, randomised, double-blind, placebo-controlled trial. *Lancet Neurol* 2023; 22:494-504.
10. Unti E, et al. Antipsychotic drugs in Huntington's disease. *Expert Rev Neurother* 2017; 17:227-237.
11. Saft C, et al. Symptomatic treatment options for Huntington's disease (guidelines of the German Neurological Society). *Neurol Res Pract* 2023; 5:61.
12. Javelot H, et al. Benefit of long-acting paliperidone in Huntington's disease: a case report. *Int Clin Psychopharmacol* 2021; 36:101-103.
13. Eddy CM, et al. Changes in mental state and behaviour in Huntington's disease. *Lancet Psychiatry* 2016; 3:1079-1086.

14. Desamericq G, et al. Guidelines for clinical pharmacological practices in Huntington's disease. *Rev Neurol (Paris)* 2016; 172:423–432.
15. Jellinger KA. The pathobiology of depression in Huntington's disease: an unresolved puzzle. *J Neural Transm* 2024; doi: 10.1007/ s00702-024-02750-w.
16. Moulton CD, et al. Systematic review of pharmacological treatments for depressive symptoms in Huntington's disease. *Mov Disord* 2014; 29:1556–1561.
17. Zadegan SA, et al. Treatment of depression in Huntington's disease: a systematic review. *J Neuropsychiatry Clin Neurosci* 2024; doi: 10.1176/ appi.neuropsych.20230120.
18. van Duijn E. Medical treatment of behavioral manifestations of Huntington disease. *Handb Clin Neurol* 2017; 144:129–139.
19. McLauchlan DJ, et al. Different depression: motivational anhedonia governs antidepressant efficacy in Huntington's disease. *Brain Commun* 2022; 4:fcac278.
20. Yahya A, et al. Electroconvulsive therapy in Huntington's disease. *Prog Neurol Psychiatry* 2021; 25:33–38.
21. Oosterloo M, et al. Obsessive-compulsive and perseverative behaviors in Huntington's disease. *J Huntingtons Dis* 2019; 8:1–7.
22. Karagas NE, et al. Irritability in Huntington's disease. *J Huntingtons Dis* 2020; 9:107–113.
23. Fisher CA, et al. Aggression in Huntington's disease: a systematic review of rates of aggression and treatment methods. *J Huntingtons Dis* 2014; 3:319–332.
24. Connolly A, et al. Meta-analysis and systematic review of vesicular monoamine transporter (VMAT-2) inhibitors in schizophrenia and psychosis. *Psychopharmacology (Berl)* 2024; 241:225–241.
25. Ross CA, et al. Huntington disease: natural history, biomarkers and prospects for therapeutics. *Nat Rev Neurol* 2014; 10:204–216.
26. Van der Vaart T, et al. Treatment of cognitive deficits in genetic disorders: a systematic review of clinical trials of diet and drug treatments. *JAMA Neurol* 2015; 72:1052–1060.
27. Li Y, et al. Cholinesterase inhibitors for rarer dementias associated with neurological conditions. *Cochrane Database Syst Rev* 2015; 3:CD009444.
28. O'Brien JT, et al. Clinical practice with anti-dementia drugs: a revised (third) consensus statement from the British Association for Psychopharmacology. *J Psychopharmacol* 2017; 31:147–168.

---

Revision #1

Created 2026-01-04 20:17:47 UTC by Omar Ayman

Updated 2026-01-04 20:17:47 UTC by Omar Ayman